Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus FOCINVEZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus FOCINVEZ.
AMPHOTEC vs FOCINVEZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
FOCINVEZ is a small-molecule inhibitor of the interaction between the N-terminal domain of the androgen receptor (AR) and the AR N-terminal domain coactivator binding site, thereby blocking AR-mediated gene transcription and inhibiting prostate cancer cell growth.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Intravenous: 1.5 mg/kg every 6 hours; maximum single dose: 200 mg.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Terminal elimination half-life: 12-15 hours; allows twice-daily dosing in most patients, extended in renal impairment (up to 30-40 hours in severe impairment).
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Renal: 70% (unchanged drug), Biliary/Fecal: 20% (metabolites), Other: 10% (minor pathways).
Category C
Category C
Antifungal
Antifungal